Quick and simple synthesis of 11C-(+)-α- dihydrotetrabenazine to be used as a pet radioligand of vesicular monoamine transporters;Síntesis rápida y simplificada de 11C-(+)-α- dihidrotetrabenazina para su utilización como radioligando PET de los transportadores vesiculares de monoaminas

Revista Espanola de Medicina Nuclear

Volumn 27, Issue 1, 2008, Pages 13-21

  Quincoces Fernandez G ^a   Collantes, M ^a   Catalan R ^a   Ecay, M ^a   Prieto, E ^a   Martino, E ^a   Blesa, F J ^a   Alvarez Erviti L ^a   Areses, P ^a   Arbizu, J ^a   Obeso, J A ^a   Marti Climent J M ^a   Richter, J A ^a   Penuelas I ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

11C (+)dihydrotetrabenazine; Monoamine transporters VMAT2; Positron emission tomography; Synthesis

Indexed keywords

CARBON 11; DIHYDROTETRABENAZINE (2 HYDROXY 3 ISOBUTYL 9,10 DIMETHOXY 1,3,4,6,7 HEXAHYDRO 11BH BENZO[A] QUINOLIZINE C 11; DIMETHYL SULFOXIDE; POTASSIUM HYDROXIDE; RADIOLIGAND; TRACER; UNCLASSIFIED DRUG; VESICULAR MONOAMINE TRANSPORTER; VESICULAR MONOAMINE TRANSPORTER 2;

ARTICLE; BINDING AFFINITY; BINDING SITE; CHEMICAL REACTION; GAS CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ISOTOPE LABELING; LIPOPHILICITY; METHYLATION; POSITRON EMISSION TOMOGRAPHY; PURIFICATION; SOLID PHASE EXTRACTION; SYNTHESIS;

EID: 42549104658     PISSN: 02126982     EISSN: 1578200X     Source Type: Journal    
DOI: 10.1157/13114365     Document Type: Article

References (34)

1. Peter D, Vu T, Edwards RH. Chimeric vesicular monoamine transporters identify structural domains that influence substrate affinity and sensitivity to tetrabenazine. The American Society for Biochemistry and Molecular Biology. 1996;9:2979-86.
2. Scherman D. Dyhidrotetrabenazine binding and monoamine uptake in mouse brain regions. J Neurochem. 1986;47:331-9.
3. Scherman D, Gasnier B, Jaudon P, Henry JP. Hydrophobicity of the tetrabenazine-binding site of the chromaffin granule monoamine transporter. Mol Pharmacol. 1988;33:72-7.
4. Thiriot DS, Ruoho AE. Mutagenesis and derivatization of human vesicle monoamine transporter 2 (VMAT2) cysteines identifies transporter domains involved in tetrabenazine binding and substrate transport. J Biol Chem. 2001;276:27304-15.
5. Kelly RB. Storage and release of neurotransmitters. Cell. 1993;10 Suppl:43-53.
6. Sievert MK, Thiriot DS, Edwards RH, Ruofo AE. High-efficiency expression and characterization of the synaptic-vesicle monoamine transporter from baculovirus-infected insect cells. Biochem. 1998;330:959-66.
7. Erickson JD. A chimeric vesicular monoamine transporter dissociates sensitivity to tetrabenazine and unsubstituted aromatic amines. Adv Pharmacol. 1998;42:227-32.
8. Scherman D, Desnos C, Darchen F, Pollak P, Javoy-Agid F, Agid Y. Striatal dopamine deficiency in Parkinson's disease: role of aging. Ann Neurol. 1998;26:551-7.
9. Henry JP, Scherman D. Radioligands of the vesicular monoamine transporter and their use as markers of monoamine storage vesicles. Biochem Pharmacol. 1989;38:2395-404.
10. Taylor SF, Koeppe RA, Tandon R, Zubieta JK, Frey KA. In vivo measurement of the vesicular monoamine transporter in schizophrenia. Neuropsychopharmacology. 2000;23: 667-75.
11. Takahashi N, Uhl G. Murine vesicular monoamine transpoter 2: molecular cloning and genomic structure. Brain Res Mol Brain Res. 1997;49:7-14.
12. 11C]dihydrotetrabenazine by dynamic PET: measurement of monoamine transporter. J Cereb Blood Flow Metab. 1996;16:1288-99.
13. Volkow ND, Ding YS, Fowler JS, Wang GJ, Logan J, Gatley SJ, et al. A new PET ligand for the dopamine transporter: studies in the human brain. J Nucl Med. 1995;36:2162-8.
14. Bohnen NI, Albin RL, Koeppe RA, Wernette KA, Kilbourn MR, Minoshima S, et al. Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease. J Cereb Blood Flow Metab. 2006;26:1-15.
15. 11C] tetrabenazine as an in vivo radioligand for the vesicular monoamine transporter. Nucl Med Biol. 1993;21:151-6.
16. Kilbourn M, Lee L, Heeg MJ, Jewett DM. Absolute configuration of (+)-α-Dihidrotetrabenazine, an active metabolite of tetrabenazine. Chirality. 1997;9:59-62.
17. 11C]Dihydrotetrabenazine. J Cereb Blood Flow Metab. 1999;19:1376-84.
18. Frey KA, Koeppe RA, Kilbourn MR, Vander Borght TM, Albin RL, Gilman S, et al. Reduction of presynaptic monoaminergic vesicles in the striata of Parkinsonian patients and in normal human aging. J Cereb Blood Flow Metab. 1995;15:S38.
19. Frey KA, Koeppe RA, Kilbourn MR, Vander Borght TM, Albin RL, Gilman S, et al. Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging. Ann Neurol. 1996;40:873-84.
20. Lang AE. Clinical rating scales and videotape analysis. En: Koller WC, Paulson G, editores. Therapy of Movement Disorders. 2nd ed. New York: Marcel Decker; 1995. p. 21-46.
21. Frey KA, Koeppe RA, Albin RL, Kilbourn MR. Losses of VMAT2 in Parkinson's disease and its progression (Abstract). Eur J Nucl Med. 2000;27:927.
22. Leenders KL, Salmon EP, Tyrrell P, Perani D, Brooks DJ, Sager H, et al. The nigroestriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease. Arch Neurol. 1990;47:1290-8.
23. Scherman D, Desnos C, Darchen F, Pollak P, Javoy-Agid F, Agid Y. Striatal dopamine deficiency in Parkinson's disease; role of aging. Ann Neurol. 1989;36:2252-60.
24. 11C] tetrabenazine to vesicular monoamine transporters in mouse brain. Life Sci. 1992;51:593-600.
25. 11C-WIN 35,428 reveals marked declines in mild Parkinson's disease. Ann Neurol. 1993;34:423-31.
26. Garnett ES, Firnau G, Nahmias C. Dopamina visualized in the basal ganglia of living man. Nature. 1983;305:137-8.
27. 11C]DTBZ-PET correlates of levodopa responses in asymmetric Parkinson's disease. Brain. 2003;126:2648-55.
28. Brooks DJ, Frey KA, Marek KL, Oakes D, Paty D, Prentice R, et al. Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease. Exp Neurol. 2003;184 Suppl 1:S68-79.
29. Lee CS, Samii A, Sossi A, Ruth TJ, Schulzer M, Holden JE, et al. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann Neurol. 2000;47:493-503.
30. Vander Borght T, Kilbourn M, Desmond T, Kuhl D, Frey K. The vesicular monoamine transporter is not regulated by dopaminergic drug treatments. Eur J Pharmacol. 1995;294:577-83.
31. De la Fuente Fernández R, Furtado S, Guttman M, Furukawa Y, Lee CS, Calne DB, et al. VMAT2 binding is elevated in Dopa-Responsive dystonia: Visualizing empty vesicles by PET. Synapse. 2003;49:20-8.
32. 11C]dihydrotetrabenazine (DTBZ). Nucl Med Biol. 1997;24:197-9.
33. Da Silva JN, Carey JE, Scherman PS, Pisani TJ, Kilbourn MR. Characterizacion of [11C]tetrabenazina as an in vivo radioligand for the vesicular monoamine transporter. Nucl Med Biol. 1994;21:151-6.
34. 11C] Tetrabenazine, a vesicular monoamine uptake inhibitor, for PET imaging studies. Appl Radiat Isot. 1992;44:673-9.